Gut Microbiota Predicts the Risk of Future COVID-19 Hospitalization and Mortality: Insights From the Population-Based HELIUS Study - Scorecard - MDSpire
Advertisement
Gut Microbiota Predicts the Risk of Future COVID-19 Hospitalization and Mortality: Insights From the Population-Based HELIUS Study
Clinical Scorecard: Gut Microbiome Composition as a Predictor of Future Hospitalization and Mortality Due to COVID-19: Findings from the HELIUS Population Study
At a Glance
Category
Detail
Condition
Severe COVID-19 (hospitalization or mortality)
Key Mechanisms
Gut microbiota composition, specifically abundance of butyrate-producing anaerobic bacteria influencing immune response
Target Population
Adults aged 18–70 years from a multiethnic urban population (HELIUS cohort)
Care Setting
Population-based cohort with linkage to national hospitalization and mortality registries
Key Highlights
Lower abundance of butyrate-producing gut bacteria is associated with increased risk of severe COVID-19.
Higher gut microbiota diversity correlates with reduced risk of severe COVID-19, though significance diminishes after adjusting for confounders.
Gut microbiota alterations precede severe COVID-19 and may serve as novel targets for prevention.
Guideline-Based Recommendations
Diagnosis
Consider gut microbiota profiling, focusing on butyrate-producing bacteria, as a potential biomarker for risk stratification of severe COVID-19.
Management
Targeting gut microbiota composition, especially enhancing butyrate-producing bacteria, may represent a preventive strategy against severe COVID-19.
Monitoring & Follow-up
Monitor gut microbiota composition changes in at-risk populations to identify susceptibility to severe COVID-19.
Risks
Reduced abundance of butyrate-producing bacteria and disrupted gut microbiota composition increase risk of severe COVID-19 outcomes.
Patient & Prescribing Data
Multiethnic adults aged 18–70 years in urban settings
Enhancing butyrate-producing gut bacteria may reduce risk of severe COVID-19 hospitalization and mortality; however, clinical interventions require further validation.
Clinical Best Practices
Incorporate assessment of gut microbiota composition in research and possibly clinical risk assessment for COVID-19 severity.
Consider interventions that support anaerobic butyrate-producing bacteria to potentially strengthen host defenses against viral pneumonia.
Adjust for confounding factors such as age, sex, ethnicity, BMI, and comorbidities when evaluating microbiota-related risk.
A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.
